liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Decreased CSF-ß-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of ß-amyloid induced by disparate mechanisms
Sjögren, M., Institute of Clinical Neuroscience, Göteborg University, Sahlgrenska University Hospital, Mölndal, Sweden, Institute of Clinical Neuroscience, Section Psychiatry, Göteborg University at Sahlgrenska Universitetssjukhuset/Mölndal, SE-43180 Mölndal, Sweden.
Institute of Clinical Neuroscience, Göteborg University, Sahlgrenska University Hospital, Mölndal, Sweden.
Institute of Clinical Neuroscience, Göteborg University, Sahlgrenska University Hospital, Mölndal, Sweden.
Linköping University, Faculty of Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Geriatric . Östergötlands Läns Landsting, Local Health Care Services in Central Östergötland, Department of Geriatric Medicine.
Show others and affiliations
2002 (English)In: Dementia and Geriatric Cognitive Disorders, ISSN 1420-8008, E-ISSN 1421-9824, Vol. 13, no 2, 112-118 p.Article in journal (Refereed) Published
Abstract [en]

Both tau and ß-amyloid 42 (Aß42) have been implicated in Alzheimer's disease (AD) and tau alone in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). These proteins can be measured in the cerebrospinal fluid (CSF), differences from normal CSF levels may reflect pathophysiological mechanisms. Using ELISAs, we investigated the levels of total CSF-tau (here referred to as tau), phosphorylated CSF-tau (phospho-tau), and Aß42 in patients with AD (n = 19), FTD (n = 14), ALS (n = 11) and Parkinson's disease (PD, n = 15) and in age-matched controls (n = 17). Both CSF-tau and CSF-phosphotau were increased in AD compared with FTD (p < 0.001), ALS (p < 0.001), PD (p < 0.001) and controls (p < 0.001). CSF-Aß42 was markedly decreased in AD and ALS (both p < 0.001) and slightly decreased in FTD (p < 0.01) and PD (p < 0.05) compared with controls. Using CSF-phosphotau may improve the differentiation of AD from FTD and ALS in clinical praxis. Furthermore, decreased CSF-Aß42 levels may be common in neurode-generative disorders possibly reflecting changes in the metabolism of ß-amyloid or axonal degeneration. Copyright © 2002 S. Karger AG, Basel.

Place, publisher, year, edition, pages
2002. Vol. 13, no 2, 112-118 p.
Keyword [en]
ß-Amyloid, Alzheimer's disease, Amyotrophic lateral sclerosis, Cerebrospinal fluid, Dementia, Frontotemporal, Hyperphosphorylated tau, Neurodegenerative, Tau
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-47072DOI: 10.1159/000048642OAI: oai:DiVA.org:liu-47072DiVA: diva2:267968
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2017-12-13

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Granerus, Ann-Kathrine

Search in DiVA

By author/editor
Granerus, Ann-Kathrine
By organisation
Faculty of Health SciencesGeriatric Department of Geriatric Medicine
In the same journal
Dementia and Geriatric Cognitive Disorders
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 36 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf